The FDA approval of belatacept has thus spurred desire for developing a clinically translatable strategy to inhibit the CD154 and CD40 pathway in order to harness this synergy to achieve maximum benefit in clinical application

The FDA approval of belatacept has thus spurred desire for developing a clinically translatable strategy to inhibit the CD154 and CD40 pathway in order to harness this synergy to achieve maximum benefit in clinical application. decade has resulted in substantial